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Abstract It is, by now, well established that mold toxins
(mycotoxins) can cause significant adverse health effects. In
this study, 15 subjects who developed an attention deficit
disorder (ADD) and slowing of reaction time at the time of
exposure to mold toxins were identified. Deficits in attention
span and reaction time were documented not only by taking
a careful history, but also by performing a Test of Variables
of Attention (TOVA). The TOVA test provides an objective
measure of these two variables. It was found that mold-
exposed subjects show statistically significant decreases in
attention span and significant increases in reaction time to
stimuli compared to controls. After ten sessions of hyper-
baric oxygen treatment (HBOT), a statistically significant
improvement was seen in both measures. This preliminary
study suggests promising outcomes in treating mold-exposed
patients with hyperbaric oxygen.
Introduction
Toxic chemical exposure such as mold and mycotoxins can
significantly affect brain function in children and adults.
Mycotoxins are secondary metabolites of fungi, usually
molds, which can cause injury to animals or humans [1]. It
has been shown that these effects may last for years after
toxic exposure has ceased [2].
Exposure to toxins, including mold, can lead to
significant long-lasting impairment of brain function, often
inducing temporary to permanent disability. Typical com-
plaints include impairment of short-term memory, intermit-
tent disorientation, disturbed balance and coordination,
inability to multi-task, and impairment of attention span
and reaction time. Sick building syndrome (SBS) may be
caused by exposure to mold and mold toxins. Symptoms of
SBS, a widely described but poorly understood constella-
tion of symptoms that has been observed in certain persons
in “sick” buildings, include headaches, poor concentration,
fatigue, memory loss, dry skin, and itchy eyes [3, 4]. This is
seen in adults as well as young people.
Toxic opportunistic molds include: Stachybotrys charta-
rum, Aspergillus species (A. fumigatus, A. flavus, A. niger,
A. versicolor, etc.), Cladosporium, Alternaria, Penicillium,
Trichoderma, Fusarium graminearum,e t c .[ 5]. These
molds flourish in moist and damp environments and may
lead to a number of mycotoxicoses, a collective name for
all of the diseases caused by toxic molds [5].
After investigating the health complaints of 209 patients
with confirmed exposure to mixed mold infestation, a
recent study concluded that exposure to mixed molds and
their associated mycotoxins in water-damaged buildings
leads to multiple health problems involving the central
nervous system and the pulmonary system [6]. Patients
typically display signs of pathology, including headaches,
gastrointestinal and neuromuscular abnormalities, and
various other complaints [7].
Objective techniques such as brainstem auditory evoked
response (BAER) tests have indicated abnormalities in
patients exposed to toxic opportunistic molds through
indoor air contamination [5]. Clinical studies carried out
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series of neurophysiologic tests such as electroencephalo-
gram (EEG), brainstem evoked potential (BAEP), visual
evoked potential (VEP), and somatosensory evoked poten-
tial (SSEP), rendered abnormal results, indicating signifi-
cant neurological defects and revealing the extent to which
toxic molds can neurologically and behaviorally affect
children [8]. There is evidence of diffuse polyneuropathy
and slow motor conduction, indicating significant neuro-
logical deficits in all patients with exposure to toxic molds
[8]. Myconeurotoxicity may result from effects of the
mycotoxins acting directly on the elements of the nervous
system or acting on other biological systems, which then
adversely affect the nervous system [9].
In many of the mold-exposed patients in question,
attention span and reaction time have become impaired.
Attention deficit disorder (ADD) is typically diagnosed by
taking a full history complemented with psychometric
testing. Although most diagnoses occur during adolescence,
ADD can occur in adults [10].
Having previously found that functional brain scans
(SPECT) are abnormal in mold-exposed patients and
improve after hyperbaric oxygen treatment (HBOT) [11],
it was unknown whether the Test of Variables of Attention
(TOVA) could also improve after HBOT. A recent pilot
study showed improvement of TOVA after HBOT. How-
ever, this study was too small to allow for statistical
analysis, having been implemented in only several subjects,
as opposed to the current study, which includes 15 adults.
Materials and methods
Subjects
Fifteen adults (ages 18 to 58 years) were entered into the
study after it was established that they had been exposed to
mold, mycotoxins, and other related byproducts and had
become ill as a result. The subjects were recruited by direct
referrals to the corresponding author from practicing
physicians, and out of those, only subjects confirmed to
have been exposed to mold were submitted to the study.
Participants consented to participate in the research study.
The UCLA IRB approved the consent forms and this study.
Although subjects were not specifically evaluated for
depression or other cognitive deficiencies, symptoms of
such disorders were not apparent during the clinical
evaluation. All potential candidates were entered into the
experimental group with the ages of those chosen for
the sample size following a fairly normal distribution. The
testing of the patients’ residence, work site, and school (in
the case of exposed students) confirmed the presence of
mold and mycotoxins upon evaluation.
Exposure and immune reaction to mold and mold toxins
was established by performing specific antibody studies (to
individual molds and mold toxins). Establishing that subjects
possessed adverse health effects due to mold exposure
involved using antibodies against molds and mycotoxins.
Subjectswerereferredforimmunologicalevaluationandwere
confirmed to have mold antibodies in greater concentration
than in healthy blood donors [12]. Since the antibodies
studied were concluded to be explicit to mold antigens and
mycotoxins, they were understandably used as indicators for
toxin-exposed patients eligible to be entered into the study.
Ill effects from exposure were measured with objective
tests, including functional brain scans (SPECT) [13],
pulmonary function tests, etc. One of the tests commonly
used is the TOVA [14], a computerized simulation which
can be done in the office. With the research advisor having
seen more than 500 patients with a history of mold
exposure in recent years, we noticed that many had
developed a clinical ADD which was confirmed by an
abnormal TOVA. TOVA tests were administered in a quiet
setting with the examiner observing the patient during the
session. The tests were repeated after HBOT had been
given for ten consecutive (except for weekends) days. All
TOVA tests were done during the morning hours.
TOVA measures include the variability of response time
(consistency), response time, commission (impulsivity), errors
of omission (inattention), post-commission response times,
multiple and anticipatory responses, and an attention deficit
hyperactivity disorder (ADHD) score, which is a comparison
to an age/gender-specific ADHD group. A compilation of the
above results is calculated and called the D prime score that
provides an overall assessment of the subject.
The TOVA is composed of a 21.6-min-long, very simple
“computer game” that measures the subject’s responses to
visual stimuli. These measurements are then compared to
the measurements of a group of people without attention
disorders who took the TOVA and a printout of the results
is generated by the program. The TOVA is extensively
normed for both children and adults (ages 4 to 80+ years).
It precisely measures reaction times (±1 ms) and it is
language- and culture-free.
The TOVA uses geometric stimuli to minimize the effects
of cultural differences and learning problems, and contains
two test conditions: target infrequent and target frequent.
When a subject responds to the nontarget, it is called an error
of commission and is a measure of impulsivity. Thus, the
ability to pay attention to a boring, repetitive task is best
measured in the first half of the TOVA, while the ability to
inhibit oneself is best measured in the second half.
The TOVA uses a fixed, mid-range interstimulus interval
(2 s) and visual stimuli. The stimuli are nonsequential,
simple geometric configurations and monochromatic. Since
these features, along with the use of a 2.5-min practice
2 Eur J Clin Microbiol Infect Dis (2011) 30:1–6round, minimize practice effects, the TOVA can be used for
serial measurements.
All subjects agreed to have their results published and
provided consent to be treated by hyperbaric oxygen,
having been informed of any potential side effects.
Statistical analysis of TOVA results was performed by
using a paired samples t-test via the Statistical Package for
the Social Sciences (SPSS) software program.
Treatment protocol
HBOT was administered in a portable chamber into which
air was delivered to a pressure reading of 1.3 ATM. The
pressure was gently increased to the above value over about
15 min after the patient had entered the chamber. One
hundred percent oxygen was delivered into the chamber
and was measured to have a concentration of 24–34% after
it had been diluted in the chamber air. Oxygen was not
delivered by mask or nasal canals, allowing the patient to
move freely about the chamber. The patient remained in the
chamber for 1 h, after which the pressure was gently
decreased before the patient exited the chamber.
The treatment protocol shown in Table 1 illustrates the
differences from traditional HBOT. Because both pressure and
oxygen are lower than in traditional chambers, the term “mild
HBOT” (mHBOT) has been used. Treatments were rendered
once or twice a day with approximately 4 h separating the
treatments on a given day. All patients in this study were
treated with ten consecutive daily treatments )except on
weekends_. Patients continued on whatever medical treatment
they had been on and, therefore, no new treatment modality
was introduced during mHBOT.
Results
After ten treatment sessions of mHBOT, the preliminary
results showed that the 15 individuals in the study
significantly improved in attention span, reaction time,
consistency, and an overall D prime score assessed via the
TOVA.
The effect of ten treatments of mHBOT on patient
inattention, reaction time, variability, and D prime score as
tested by the TOVA in subjects with mold exposure is
illustrated in Fig. 1.
To test whether the average attention span was higher in
the after mHBOT condition (M=96.47, SD=21.11) than in
the before mHBOT condition (M=72.67, SD=32.35), the
means of these two conditions were compared using a
paired samples t-test. This analysis revealed that, on
average, participants significantly improved their attention
span after ten mHBOT sessions, t(14) = 3.55, p<0.05. The
same test was used to analyze the change in scores of
reaction time [t(14) = 4.41], consistency [t(14) = 4.82], and
overall D prime score [t(14) = 3.58], and showed a p<0.05
value for all categories.
Discussion
While ADD is usually thought of as a disorder in the
young, it can certainly occur in adults. In this case, it should
be considered as acquired, i.e., secondary to toxic exposure.
ADHD in adults is reasoned to be similar in nature to the
commonly known childhood disorder with regard to
cognitive and psychiatric findings [15].
In recent years, there have been an increasing number of
patients who were exposed to mold and mold toxins. Many
of these patients complain of impaired brain function and
turn out to have abnormal neuropsychological tests,
abnormal SPECT brain scans, and abnormal TOVA tests.
The TOVA test may be repeated many times and remains a
valid indicator of attention span and reaction time because
there is no learning experience with this test. Therefore, it is
ideal for following a patient before, during, and after
treatment. Hence, mold exposure can result in toxic
Table 1 Portable hyperbaric oxygen chambers were used as a form of
mild hyperbaric oxygen treatment (mHBOT) with the given con-
ditions compared to traditional HBOT. Atmosphere absolute (ATA) of
1 ATA is the atmospheric pressure at sea level measured with a
barometer. mHBOT uses 1.3 ATA compared to 2–3 ATA in traditional
chambers. Pound per square inch gauge (PSIG) is the pressure
referenced to ambient air pressure indicated by a pressure gauge using
atmospheric pressure as a base. This value in mHBOT, 4.7, is much
milder than the 14.7–29.4 value in traditional HBOT. Feet of sea water
(FSW) is used to indicate either an actual depth, or in this case, a
pressure equal to that depth as can be used to describe a hyperbaric
chamber. Again, less pressure is applied to the chambers used in this
study. The oxygen concentration is mildly elevated from 21% in air to
24%, yet, is much less than the 100% oxygen concentration used in
traditional chambers
Sea level Mild HBOT Traditional HBOT
ATA 1.0 1.3 2.0–3.0
PSIG 0 4.7 14.7–29.4
FSW 0 11 33-66
Oxygen concentration 21% 24% 100%
Eur J Clin Microbiol Infect Dis (2011) 30:1–6 3encephalopathy and ADD, which can be treated with
mHBOT.
TOVA tests support the idea of abnormal physiological
behavior characteristic of patients with a history of mold
exposure. Other studies likened to revealing these abnor-
malities resulted in similar conclusions using different
techniques were done by Anyanwu et al. As mentioned
earlier, contemporary objective neurophysiological tests
include EEG, BAEP, VEP, and SSEP. Questionnaires were
utilized to analyze response times for abnormalities, as well
as the examination of EEGs. Whereas this study involved
abnormality regarding response times, in all of Anyanwu et
al.’s patients, delays were found in conduction parameters
within the brain. BAEP showed waveform abnormalities in
90% of their patients, VEP showed abnormalities with
decreased latencies bilaterally. In the right tibial, there was
a slowing of conduction at an average of 36.9 ms, the right
distal sensory latencies were prolonged compared to the
ulnars bilaterally in contrast to the lack of any latencies in
the control group [5]. Motor conductions were significantly
slow and neurological deficits affecting the behavioral
status of children were attributed to the extent of their
toxic mold exposure.
Multiple articles endorse the treatment of mold, specif-
ically mucormycosis [16, 17], zygomycosis [18, 19], and
candidiasis [20], with hyperbaric oxygen [21]. While some
of the mechanisms of action of HBOT, as they apply to the
healing and reversal of symptoms, are yet to be discovered,
it is known that HBOT has many effects on the body.
HBOT greatly increases oxygen concentration in all body
tissues, even with reduced or blocked blood flow. It
stimulates the growth of new blood vessels to locations
with reduced circulation, improving blood flow to areas
with arterial blockage. There is a rebound arterial dilation
after HBOT, resulting in an increased blood vessel diameter
greater than when therapy began, improving blood flow to
compromised organs. HBOT stimulates an adaptive in-
crease in superoxide dismutase (SOD), one of the body’s
principal, internally produced antioxidants and free radical
scavengers [22]. Finally, HBOT greatly aids the treatment
of infection by enhancing white blood cell action and
potentiating germ-killing antibiotics.
The potential mechanism that may underlie the effec-
tiveness of hyperbaric oxygen on ADD symptoms is not
clear. HBOT may play a role in the repair or reconstruction
of injured lower motor neurons [23] and has been suggested
to provide an effective strategy for the prevention and
treatment of numerous neurologic handicaps [24].
Stem or progenitor cells have been found in the adult
brain in the past decade that can lead to neural regeneration
[25], a recovery process that is oxygen-dependent. Capil-
lary density can be increased in the adult mammalian brain
[26], aiding nutrient delivery to regenerating tissues. HBOT
has been shown to be useful in the treatment of neurologic
injury, even if applied in the nonacute period [27, 28].
The results obtained through the current study are
preliminary due to the lack of a control group with a
possible placebo structure. It is important to take the
implications of this small study and implement a controlled,
randomized, double-blind experimental study to test the
true therapeutic capabilities of hyperbaric oxygen medicine
on patients with toxic mold exposure. Control studies with
hyperbaric oxygen are very difficult to perform and have
been recently discussed by Clarke [29].
Fig. 1 After ten treatment sessions of mild hyperbaric oxygen
treatment (mHBOT), the 15 individuals in the study significantly
improved (indicated by *) in attention span, reaction time, consisten-
cy, and an overall D prime score assessed via the Test of Variables of
Attention (TOVA). Each subject was compared to his/her own TOVA
score before treatment. This figure shows the pooled scores of all 15
subjects before and after all HBOT sessions. A higher score indicates
an increase in attention, shortened reaction time, higher consistency,
and increased D prime score. The scale from 0–100 on the y-axis
denotes deviation from standard scores exhibited by TOVA controls,
where 100 = no abnormality
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controlled trial, children with autism who received hyper-
baric treatment at 1.3 ATM and 24% oxygen for 40 hourly
sessions had significant improvements in overall function-
ing, receptive language, social interaction, eye contact, and
sensory/cognitive awareness compared to children who
received slightly pressurized room air [30]. Other studies
have also provided evidence for the hyperbaric treatment of
autism [31–35].
While not new, HBOT has only lately begun to gain
recognition for the treatment of chronic degenerative health
problems related to diabetic gangrene [36], atherosclerosis
[37], stroke [38], chronic vascular wound management
[39], diabetic foot ulcers [36], wound healing [40], cerebral
palsy [41], brain injury [42], multiple sclerosis [43],
macular degeneration [44], and many other disorders.
Wherever blood flow and oxygen delivery to vital organs
are reduced, function and healing can potentially be aided
with HBOT.
Memory, reaction time, and visual motor speed assess-
ments were compared before, during, and after hyperbaric
oxygen therapy in a case of fetal alcohol syndrome
involving a teenage male patient [45]. The authors were
able to show that this patient benefited from a short course
of low-pressure hyperbaric oxygen therapy, sustained
durable cognitive improvements, and continued to exhibit
improvement with another short course of treatments [45].
Previous literature has shown HBOT to be effective in
improving cerebral palsy using three-dimensional displays
of SPECT of the cerebral hemispheres of patients before
and after treatment with mHBOT [13]. The computer
program used in this study makes a regional quantitative
comparison of an individual’s SPECT scan with a group of
more than 20 controls. Using the same procedure for the 15
patients suffering from toxic injury due to mold exposure,
the baseline impairment of perfusion moved into the normal
zones after treatment with HBOT. The quantitative aspects
of this study are currently being studied.
Low-pressure HBOT is a therapy with an extremely low
risk profile and relatively low cost, with potential benefits
that seem to be significant and measurable for a condition
with few other treatments at our disposal. In this study, 15
adults with symptoms associated with exposure to mold
and mycotoxins benefited from a short course of low-
pressure HBOT and sustained durable cognitive improve-
ments. Given the implications, these results should receive
consideration for broader study.
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